Literature DB >> 30796162

Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamics.

Chun-Xiang Wu1,2, Jingling Liao1,2,3, Yangshin Park1,2, Xylena Reed4, Victoria A Engel1,2, Neo C Hoang1,2, Yuichiro Takagi1, Steven M Johnson1, Mu Wang1,5, Mark Federici6, R Jeremy Nichols7, Ruslan Sanishvili8, Mark R Cookson4, Quyen Q Hoang9,2,10.   

Abstract

Mutation in leucine-rich repeat kinase 2 (LRRK2) is a common cause of familial Parkinson's disease (PD). Recently, we showed that a disease-associated mutation R1441H rendered the GTPase domain of LRRK2 catalytically less active and thereby trapping it in a more persistently "on" conformation. However, the mechanism involved and characteristics of this on conformation remained unknown. Here, we report that the Ras of complex protein (ROC) domain of LRRK2 exists in a dynamic dimer-monomer equilibrium that is oppositely driven by GDP and GTP binding. We also observed that the PD-associated mutations at residue 1441 impair this dynamic and shift the conformation of ROC to a GTP-bound-like monomeric conformation. Moreover, we show that residue Arg-1441 is critical for regulating the conformational dynamics of ROC. In summary, our results reveal that the PD-associated substitutions at Arg-1441 of LRRK2 alter monomer-dimer dynamics and thereby trap its GTPase domain in an activated state.

Entities:  

Keywords:  GTPase; Parkinson disease; Ras of complex proteins (ROC); conformational change; conformational dynamics; disease mutation; enzyme activation; kinase; leucine-rich repeat kinase 2 (LRRK2); molecular dynamics

Mesh:

Substances:

Year:  2019        PMID: 30796162      PMCID: PMC6463707          DOI: 10.1074/jbc.RA119.007631

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.

Authors:  Andrew B West; Darren J Moore; Catherine Choi; Shaida A Andrabi; Xiaojie Li; Dustin Dikeman; Saskia Biskup; Zhenshui Zhang; Kah-Leong Lim; Valina L Dawson; Ted M Dawson
Journal:  Hum Mol Genet       Date:  2007-01-02       Impact factor: 6.150

2.  LRRK2 autophosphorylation enhances its GTPase activity.

Authors:  Zhiyong Liu; James A Mobley; Lawrence J DeLucas; Richard A Kahn; Andrew B West
Journal:  FASEB J       Date:  2015-09-22       Impact factor: 5.191

Review 3.  The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.

Authors:  Mark R Cookson
Journal:  Nat Rev Neurosci       Date:  2010-11-19       Impact factor: 34.870

Review 4.  LRRK2 in Parkinson's disease: protein domains and functional insights.

Authors:  Ignacio F Mata; William J Wedemeyer; Matthew J Farrer; Julie P Taylor; Kathleen A Gallo
Journal:  Trends Neurosci       Date:  2006-04-17       Impact factor: 13.837

Review 5.  Mutations in LRRK2 as a cause of Parkinson's disease.

Authors:  Benoit I Giasson; Vivianna M Van Deerlin
Journal:  Neurosignals       Date:  2007-12-05

6.  Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase.

Authors:  Katja Gotthardt; Michael Weyand; Arjan Kortholt; Peter J M Van Haastert; Alfred Wittinghofer
Journal:  EMBO J       Date:  2008-07-24       Impact factor: 11.598

7.  The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2.

Authors:  Xiaorong Huang; Chunxiang Wu; Yangshin Park; Xuwei Long; Quyen Q Hoang; Jingling Liao
Journal:  FASEB J       Date:  2018-12-28       Impact factor: 5.191

8.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

9.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

10.  Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease.

Authors:  Alexandria Beilina; Iakov N Rudenko; Alice Kaganovich; Laura Civiero; Hien Chau; Suneil K Kalia; Lorraine V Kalia; Evy Lobbestael; Ruth Chia; Kelechi Ndukwe; Jinhui Ding; Mike A Nalls; Maciej Olszewski; David N Hauser; Ravindran Kumaran; Andres M Lozano; Veerle Baekelandt; Lois E Greene; Jean-Marc Taymans; Elisa Greggio; Mark R Cookson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-07       Impact factor: 11.205

View more
  7 in total

Review 1.  LRRK2 and idiopathic Parkinson's disease.

Authors:  Emily M Rocha; Matthew T Keeney; Roberto Di Maio; Briana R De Miranda; J Timothy Greenamyre
Journal:  Trends Neurosci       Date:  2022-01-04       Impact factor: 13.837

2.  Binding of the Human 14-3-3 Isoforms to Distinct Sites in the Leucine-Rich Repeat Kinase 2.

Authors:  Jascha T Manschwetus; Maximilian Wallbott; Alexandra Fachinger; Claudia Obergruber; Sabine Pautz; Daniela Bertinetti; Sven H Schmidt; Friedrich W Herberg
Journal:  Front Neurosci       Date:  2020-04-07       Impact factor: 4.677

Review 3.  Allosteric inhibition of LRRK2, where are we now.

Authors:  Ahmed Soliman; Fatma Nihan Cankara; Arjan Kortholt
Journal:  Biochem Soc Trans       Date:  2020-10-30       Impact factor: 5.407

4.  Oligomerization of Lrrk controls actin severing and α-synuclein neurotoxicity in vivo.

Authors:  Souvarish Sarkar; Farah Bardai; Abby L Olsen; Kelly M Lohr; Ying-Yi Zhang; Mel B Feany
Journal:  Mol Neurodegener       Date:  2021-05-24       Impact factor: 14.195

5.  The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity.

Authors:  Molly FitzGibbon; Elizabeth M Earley; Hannah Ahrendt; Adrienne E D Stormo; Farbod Shavarebi; Lotus S Lum; Erik Verschueren; Danielle L Swaney; Gaia Skibinski; Abinaya Ravisankar; Jeffrey van Haren; Emily J Davis; Jeffrey R Johnson; John Von Dollen; Carson Balen; Jacob Porath; Claudia Crosio; Christian Mirescu; Ciro Iaccarino; William T Dauer; R Jeremy Nichols; Torsten Wittmann; Timothy C Cox; Steve Finkbeiner; Nevan J Krogan; Scott A Oakes; Annie Hiniker
Journal:  J Cell Biol       Date:  2022-03-10       Impact factor: 10.539

Review 6.  Molecular Pathways Involved in LRRK2-Linked Parkinson's Disease: A Systematic Review.

Authors:  Ailyn Irvita Ravinther; Hemaniswarri Dewi Dewadas; Shi Ruo Tong; Chai Nien Foo; Yu-En Lin; Cheng-Ting Chien; Yang Mooi Lim
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

7.  Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues.

Authors:  Lucia Iannotta; Alice Biosa; Jillian H Kluss; Giulia Tombesi; Alice Kaganovich; Susanna Cogo; Nicoletta Plotegher; Laura Civiero; Evy Lobbestael; Veerle Baekelandt; Mark R Cookson; Elisa Greggio
Journal:  Cells       Date:  2020-10-22       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.